Fadrozole is a synthetic non-steroidal aromatase inhibitor and active pharmaceutical ingredient (API). It inhibits the enzyme aromatase, which is responsible for the conversion of androgens into estrogens. Fadrozole has been investigated for its potential use in hormone-dependent cancers, particularly breast cancer.
Fadrozole is a potent, selective inhibitor of aromatase (CYP19A1). By reducing estrogen biosynthesis, it can decrease estrogen-dependent stimulation of certain tissues and tumors.
CAS Number: 102676-47-1
Molecular Formula: C₁₇H₁₉N₅
Molecular Weight: 293.37 g/mol
Fadrozole inhibits aromatase, the enzyme responsible for the final step in estrogen biosynthesis.
Its pharmacological effects include:
Fadrozole has been investigated primarily for:
Regulatory status and approved indications should be verified for the applicable market before making therapeutic or commercial claims.
Fadrozole is a small-molecule pharmaceutical API with defined chemical and physicochemical characteristics. Pharmaceutical-grade material requires appropriate control of identity, assay, related substances and other quality attributes.
Typical quality evaluation may include:
Pharmaceutical-grade Fadrozole should comply with the applicable approved specification and relevant regulatory requirements.
A qualified supplier should provide Certificate of Analysis (CoA), specification sheet, SDS/MSDS, batch traceability and applicable regulatory documentation.
Store Fadrozole in a tightly closed container, protected from excessive moisture, heat and direct light, according to the manufacturer's approved storage and stability requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | NLT 98.0% by HPLC |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.2% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | ≤ 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 0.5% |